Samer Tannus

ORCID: 0000-0002-4679-1851 · 4 papers in corpus
other 2020
Pretreatment with a gonadotropin-releasing hormone agonist and an aromatase inhibitor may improve outcomes in in vitro fertilization cycles of women with stage I-II endometriosis
F&S science ·doi:10.1016/j.xfss.2020.06.005

OBJECTIVE: To determine whether 2 months of pretreatment with 5 mg of letrozole daily plus leuprolide acetate at 3.75 mg monthly in women with laparoscopically confirmed American Society of Reproductive Medicine stage I-II endometriosis imp…

article 2019
Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure
Fertility and sterility ·doi:10.1016/j.fertnstert.2019.03.021

ObjectiveTo compare the influence of dual suppression with the use of GnRH agonist plus aromatase inhibitor compared with suppression with the use of GnRH agonist alone or no suppression at all in patients with idiopathic recurrent implanta…

article 2018
A comparison of pre-treatment with and without GnRH-agonist or letrozole in women with 2 failed embryo transfers undergoing a frozen cycle and no evidence of endometriosis
·doi:10.1016/j.fertnstert.2018.07.557
article 2018
A comparison of two months pretreatment with GnRH agonists with or without an aromatase inhibitor in women with ultrasound-diagnosed ovarian endometriomas undergoing IVF
Reproductive BioMedicine Online ·doi:10.1016/j.rbmo.2018.12.028

Research questionDoes the addition of an aromatase inhibitor improve IVF outcomes in women with endometriomas when pretreating them with gonadotrophin-releasing hormone agonists?DesignRetrospective two-centre cohort study involving 126 wome…